These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 27381626

  • 1. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J.
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381626
    [Abstract] [Full Text] [Related]

  • 2. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.
    Proc Natl Acad Sci U S A; 2008 Nov 04; 105(44):17079-84. PubMed ID: 18971340
    [Abstract] [Full Text] [Related]

  • 3. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.
    BMC Cancer; 2016 Oct 19; 16(1):811. PubMed ID: 27756336
    [Abstract] [Full Text] [Related]

  • 4. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.
    J Pathol; 2017 Mar 19; 241(4):511-521. PubMed ID: 27943283
    [Abstract] [Full Text] [Related]

  • 5. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    Breast Cancer Res Treat; 2018 Feb 19; 167(3):803-814. PubMed ID: 29116469
    [Abstract] [Full Text] [Related]

  • 6. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, Jacot W, Sardet C, Theillet C.
    Cancer Lett; 2024 May 01; 589():216820. PubMed ID: 38574883
    [Abstract] [Full Text] [Related]

  • 7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    Biomed Pharmacother; 2018 Mar 01; 99():543-551. PubMed ID: 29902865
    [Abstract] [Full Text] [Related]

  • 8. Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.
    Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    Cancer Res; 2019 Aug 15; 79(16):4258-4270. PubMed ID: 31213465
    [Abstract] [Full Text] [Related]

  • 9. Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
    Park HS, Lee JD, Kim JY, Park S, Kim JH, Han HJ, Choi YA, Choi AR, Sohn JH, Kim SI.
    PLoS One; 2019 Aug 15; 14(12):e0225082. PubMed ID: 31821346
    [Abstract] [Full Text] [Related]

  • 10. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
    Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.
    Cancer Discov; 2013 Jan 15; 3(1):68-81. PubMed ID: 23103855
    [Abstract] [Full Text] [Related]

  • 11. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.
    J Clin Oncol; 2017 Apr 10; 35(11):1240-1249. PubMed ID: 28221868
    [Abstract] [Full Text] [Related]

  • 12. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
    Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    Ann Oncol; 2021 Feb 10; 32(2):240-249. PubMed ID: 33242536
    [Abstract] [Full Text] [Related]

  • 13. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
    Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.
    J Clin Invest; 2016 Aug 01; 126(8):2903-18. PubMed ID: 27454287
    [Abstract] [Full Text] [Related]

  • 14. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.
    J Surg Res; 2020 Jun 01; 250():200-208. PubMed ID: 32092597
    [Abstract] [Full Text] [Related]

  • 15. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.
    Mol Cell; 2019 Jan 17; 73(2):224-237.e6. PubMed ID: 30554948
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.
    Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM.
    Clin Cancer Res; 2017 Jul 01; 23(13):3405-3415. PubMed ID: 28069724
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.
    Cell Rep; 2016 Nov 22; 17(9):2367-2381. PubMed ID: 27880910
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.